The role of chemotherapy in patients with small cell lung cancer and poor performance status

References

• Sundstrom S, Bremnes RM, Kaasa S, et al.; Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002;20(24):4665–4672.
   PubMed Web of Science ®Google Scholar
• Faivre-Finn C, Snee M, Ashcroft L, et al.; CONVERT Study Team. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116–1125.
   PubMed Web of Science ®Google Scholar
• Lara PN, Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27(15):2530–2535.
   PubMed Web of Science ®Google Scholar
• Baldotto CS, Cronemberger EH, de Biasi P, et al. Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy? Support Care Cancer. 2012;20(11):2721–2727.
   PubMed Web of Science ®Google Scholar
• Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. [cited 2018 Mar 5].
   Google Scholar
• Available from: https://tmc.gov.in/tmh/PDF/Lung-Gastric.pdf. [cited 2018 Mar 5].
   Google Scholar
• Giordano KF, Jatoi A, Adjei AA, et al. Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution. Lung Cancer. 2005;49(2):209–215.
   PubMed Web of Science ®Google Scholar
• Chakraborty S. A step-wise guide to performing survival analysis. Cancer Res Stat Treat. 2018;1:41–45.
   Google Scholar
• Dessai S, Simha V, Patil V. Stepwise cox regression analysis in SPSS. Cancer Res Stat Treat. 2019;2(1):108–170.
   Google Scholar
• Dessai S, Patil V. Testing and interpreting assumptions of COX regression analysis. Cancer Res Stat Treat. 2019;2(1):108–111.
   Google Scholar
• Agra Y, Pelayo M, Sacristan M, et al. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev. 2003;(4):CD001990.
   PubMedGoogle Scholar
• Azam F, Wong H, Green JA, et al. Poor performance status small cell lung cancer: who should we treat? J Clin Oncol. 29(15). DOI:10.1200/jco.2011.29.15_suppl.e17502
   Google Scholar
• by Bleehen NM, Girling DJ, Hopwood P, et al. Medical Research Council Lung Cancer Working Party (prepared on behalf of the working party and its collaborators. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Br J Cancer. 1996;73(3):406–413.
   PubMed Web of Science ®Google Scholar
• Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet. 1996;348(9027):563–566.
   PubMed Web of Science ®Google Scholar
• Hermes A, Bergman B, Bremnes R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol. 2008;26(26):4261–4267.
   PubMed Web of Science ®Google Scholar
• Sakuragi T, Oshita F, Nagashima S, et al. Retrospective analysis of the treatment of patients with small cell lung cancer showing poor performance status. Jpn J Clin Oncol. 1996;26(3):128–133.
   PubMed Web of Science ®Google Scholar
• Aida Y, Nakazawa K, Shiozawa T, et al. Small-cell lung cancer treatment of newly diagnosed patients with poor performance status. Case Rep Oncol. 2019;12(2):613–620.
   PubMed Web of Science ®Google Scholar
• Noda K, Nishiwaki Y, Kawahara M, et al.; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346(2):85–91.
   PubMed Web of Science ®Google Scholar
• Cerny T, Blair V, Anderson H, et al. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer. 1987;39(2):146–149.
   PubMed Web of Science ®Google Scholar
• Kawahara M, Fukuoka M, Saijo N, et al. Prognostic factors and prognostic staging system for small cell lung cancer. Jpn J Clin Oncol. 1997;27(3):158–165.
   PubMed Web of Science ®Google Scholar
• Maestu I, Pastor M, Gómez-Codina J, et al. Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol. 1997;8(6):547–553.
   PubMed Web of Science ®Google Scholar
• Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now? A review. Transl Lung Cancer Res. 2016;5(1):26–38.
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, IMpower133 Study Group, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229.
   PubMed Web of Science ®Google Scholar
• Available from: https://www.who.int/tobacco/surveillance/survey/gats/GATS_India_2016-17_FactSheet.pdf?ua=1#:∼:text=19.0%25%20of%20men%2C%202.0%25,and%2For%20smokeless%20tobacco. [cited 2020 July 30].
   Google Scholar
• Noronha V, Dikshit R, Raut N, et al. Epidemiology of lung cancer in India: focus on the differences between non-smokers and smokers: a single-centre experience. Indian J Cancer. 2012;49(1):74–81.
   PubMed Web of Science ®Google Scholar
• Noronha V, Chougule A, Joshi A, et al. Epidermal growth factor receptor mutation in small cell lung cancer patients in an indian tertiary care oncology hospital: incidence and clinical outcome. Clin Oncol. 2016;28(5):342–343.
   Web of Science ®Google Scholar
• Noronha V, Ramaswamy A, Dhekle R, et al. Initial experience of a geriatric oncology clinic in a tertiary cancer center in India. Cancer Res Stat Treat. 2020;3(2):208–217.
   Google Scholar
• Noronha V, Patil VM, Joshi A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Cin Oncol. 2020;38(2):124–136.
   PubMed Web of Science ®Google Scholar